Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: abstract who wrote (76055)	10/9/2004 11:30:08 AM
From: Alastair McIntosh	Respond to of 793824

OT abstract, the Heart Protection Study of 20,536 high-risk individuals conducted by the Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford and published in the Lancet in 2002 showed only a 1.8% reduction in mortality using simvastatin compared to a placebo. This study indicated a small benefit to a high-risk population. There is little evidence that statins benefit the population at large. In any event, I'm through with this. If you are in a high risk group you may benefit. I am only pointing out that the benefits of statins may not be what drug companies would have you believe. You may want to research the relationship between cholesterol and mortality in those 50 and over.